Sopelsa Mariani, Motter Fabiane Raquel, Barcellos Nêmora Tregnago, Leite Heloísa Marquardt, Paniz Vera Maria Vieira
Universidade do Vale do Rio dos Sinos, Programa de Pós-Graduação em Saúde Coletiva, São Leopoldo-RS, Brasil.
Epidemiol Serv Saude. 2017 Oct-Dec;26(4):759-770. doi: 10.5123/S1679-49742017000400008.
to describe the pharmacotherapeutic profile of users of the Specialized Program for Pharmaceutical Assistance, and to measure the expenditure on the most prevalent and the most expensive medications.
descriptive study conducted in São Leopoldo-RS, Brazil, with secondary data regarding information about requests accepted in 2014, through administrative proceedings; delivery notes of the State Health Department/RS were used to assess the costs.
1,528 users were included in the study, mostly women (56.7%), and the average age was 52 years (standard deviation=17.9); the most frequent diagnoses were allergic asthma (17.1%), chronic kidney disease (11.5%) and rheumatoid arthritis (8.4%); the most prevalent drug was budesonide+formoterol fumarate (18.3%); among the most prevalent drugs, the highest total monthly expense was with epoetin alfa (BRL37,922.34) and among the most expensive drugs, infliximab (BRL72,503.28).
the data show the importance of the Specialized Program for Pharmaceutical Assistance in the high-cost treatment of highly prevalent.
描述药物援助专项计划使用者的药物治疗概况，并衡量最常用和最昂贵药物的支出情况。
在巴西圣 Leopoldo-RS 进行描述性研究，利用行政程序获取 2014 年接受请求的二级数据信息；通过州卫生部/RS 的交货单评估成本。
1528 名使用者纳入研究，多数为女性（56.7%），平均年龄 52 岁（标准差 = 17.9）；最常见诊断为过敏性哮喘（17.1%）、慢性肾病（11.5%）和类风湿性关节炎（8.4%）；最常用药物为布地奈德+富马酸福莫特罗（18.3%）；在最常用药物中，每月总费用最高的是促红细胞生成素α（37,922.34 巴西雷亚尔），在最昂贵药物中，英夫利昔单抗（72,503.28 巴西雷亚尔）。
数据表明药物援助专项计划在高流行疾病的高成本治疗中的重要性。
